13087 Results

People

  1. Giralt
    Giralt
  2. Perales
    Perales
  3. Levine
    Levine
  4. Zelenetz
    Zelenetz
  5. Horwitz
    Horwitz
  6. Abdel-Wahab
    Abdel-Wahab
  7. Scheinberg
    Scheinberg
  8. Jakubowski
    Jakubowski
  9. Landau
    Landau
  10. Shah
    Shah

Groups

  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)
  7. Lymphoma (2639)
  8. Sloan Kettering Institute Faculty (2602)
  9. Executive Committee, Center for Hematologic Malignancies (2358)
  10. Survivorship Research (2328)
  1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma: Updated results of a Phase 1b/2 study
    Meeting Abstract

    Matasar, M.; Herrera, A. F.; Kamdar, M.; Mehta, A.; Assouline, S.; Fleury, I.; Kim, T. M.; Kim, W. S.; Bosch, F.; Radford, J.; more...
    Haematologica (2017)

    Fulltext@MSK | Save
  • Differentiation syndrome associated with enasidenib (AG-221), a selective inhibitor of mutant isocitrate dehydro-genase 2 (mIDH2)
    Meeting Abstract

    Fathi, A. T.; DiNardo, C. D.; Kline, I.; Kenvin, L.; Gupta, I.; Attar, E. C.; Stein, E. M.; de Botton, S.
    Haematologica (2017)

    Fulltext@MSK | Save
  • Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia: Initial results from the BFORE trial
    Meeting Abstract

    Brümmendorf, T. H.; Gambacorti-Passerini, C.; Deininger, M.; Mauro, M. J.; Chuah, C.; Kim, D. W.; Reilly, L.; Jeynes-Ellis, A.; Leip, E.; Bardy-Bouxin, N.; more...
    Haematologica (2017)

    Fulltext@MSK | Save
  • Enasidenib (AG-221) in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase 1 dose-escalation and expansion study
    Meeting Abstract

    Stein, E. M.; DiNardo, C. D.; Pollyea, D. A.; Fathi, A. T.; Roboz, G. J.; Altman, J. K.; Stone, R. M.; Flinn, I. W.; Kantarjian, H. M.; Collins, R.; more...
    Haematologica (2017)

    Fulltext@MSK | Save
  • Patients with light chain amyloidosis treated with NEOD001 achieve rapid organ responses that are independent of previous plasma cell-directed therapies
    Meeting Abstract

    Gertz, M. A.; Comenzo, R. L.; Landau, H.; Sanchorawala, V.; Weiss, B. M.; Zonder, J. A.; Walling, J.; Kinney, G. G.; Koller, M.; Schenk, D. B.; more...
    Haematologica (2017)

    Fulltext@MSK | Save
  • Vadastuximab talirine plus hypomethylating agents: A well-tolerated regimen with high remission rate in frontline older patients with acute myeloid leukemia
    Meeting Abstract

    Ravandi, F.; Stein, A.; Erba, H.; Lancet, J.; Stein, E.; Faderl, S.; Walter, R.; Advani, A.; DeAngelo, D.; Kovacsovics, T.; more...
    Haematologica (2017)

    Fulltext@MSK | Save
  • Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL
    Meeting Abstract

    Park, J.; Riviere, I.; Wang, X.; Senechal, B.; Wang, Y.; Santomasso, B.; Sadelain, M.; Brentjens, R.
    Haematologica (2017)

    Fulltext@MSK | Save
  • KIR3DL1/HLA-B subtypes govern acute myelogenous leukemia relapse after hematopoietic cell transplantation
    Journal Article

    Boudreau, J. E.; Giglio, F.; Gooley, T. A.; Stevenson, P. A.; Le Luduec, J. B.; Shaffer, B. C.; Rajalingam, R.; Hou, L.; Hurley, C. K.; Noreen, H.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Overall survival in cancer drug trials as a new surrogate end point for overall survival in the real world
    Journal Article

    Mailankody, S.; Prasad, V.
    JAMA Oncology (2017)

    Fulltext@MSK | Save
  • Results from a phase I/II open-label, dose-finding study of pralatrexate and oral bexarotene in patients with relapsed/refractory cutaneous T-cell lymphoma
    Journal Article

    Duvic, M.; Kim, Y. H.; Zinzani, P. L.; Horwitz, S. M.
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save